196 related articles for article (PubMed ID: 37322680)
1. Refractive profile of children treated with intravitreal bevacizumab for retinopathy of prematurity.
Pawar N; Somyashree D; Meenakshi R; Maheshwari D; Mohideen S; Sithiq Uduman M
Indian J Ophthalmol; 2023 Jun; 71(6):2561-2568. PubMed ID: 37322680
[TBL] [Abstract][Full Text] [Related]
2. Outcomes after Intravitreal Bevacizumab versus Laser Photocoagulation for Retinopathy of Prematurity: A 5-Year Retrospective Analysis.
Hwang CK; Hubbard GB; Hutchinson AK; Lambert SR
Ophthalmology; 2015 May; 122(5):1008-15. PubMed ID: 25687024
[TBL] [Abstract][Full Text] [Related]
3. Factors associated with refractive outcome in children treated with bevacizumab for retinopathy of prematurity: the importance of retinal vascularization.
Bayramoglu SE; Sayin N
Int Ophthalmol; 2022 Oct; 42(10):3199-3210. PubMed ID: 35579771
[TBL] [Abstract][Full Text] [Related]
4. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial.
Geloneck MM; Chuang AZ; Clark WL; Hunt MG; Norman AA; Packwood EA; Tawansy KA; Mintz-Hittner HA;
JAMA Ophthalmol; 2014 Nov; 132(11):1327-33. PubMed ID: 25103848
[TBL] [Abstract][Full Text] [Related]
5. One-year refractive outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity.
Kıran Yenice E; Petriçli İS; Kara C
Int Ophthalmol; 2023 Jul; 43(7):2197-2202. PubMed ID: 36522564
[TBL] [Abstract][Full Text] [Related]
6. Intravitreal bevacizumab for retinopathy of prematurity: refractive error results.
Harder BC; Schlichtenbrede FC; von Baltz S; Jendritza W; Jendritza B; Jonas JB
Am J Ophthalmol; 2013 Jun; 155(6):1119-1124.e1. PubMed ID: 23490192
[TBL] [Abstract][Full Text] [Related]
7. Development of refractive error in children treated for retinopathy of prematurity with anti-vascular endothelial growth factor (anti-VEGF) agents: A meta-analysis and systematic review.
Tan QQ; Christiansen SP; Wang J
PLoS One; 2019; 14(12):e0225643. PubMed ID: 31790445
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Bevacizumab, Ranibizumab, and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity in Turkey.
Gunay M; Sukgen EA; Celik G; Kocluk Y
Curr Eye Res; 2017 Mar; 42(3):462-469. PubMed ID: 27420302
[TBL] [Abstract][Full Text] [Related]
9. Longitudinal Change of Refractive Error in Retinopathy of Prematurity Treated With Intravitreal Bevacizumab or Laser Photocoagulation.
Wiecek E; Akula JD; Vanderveen DK; Mantagos IS; Wu C; Curran AL; De Bruyn H; Peterson B; Fulton AB
Am J Ophthalmol; 2022 Aug; 240():252-259. PubMed ID: 35367438
[TBL] [Abstract][Full Text] [Related]
10. Refractive errors after the use of bevacizumab for the treatment of retinopathy of prematurity: 2-year outcomes.
Chen YH; Chen SN; Lien RI; Shih CP; Chao AN; Chen KJ; Hwang YS; Wang NK; Chen YP; Lee KH; Chuang CC; Chen TL; Lai CC; Wu WC
Eye (Lond); 2014 Sep; 28(9):1080-6; quiz 1087. PubMed ID: 25104736
[TBL] [Abstract][Full Text] [Related]
11. Comparison of 5-year safety and efficacy of laser photocoagulation and intravitreal bevacizumab injection in retinopathy of prematurity.
Murakami T; Sugiura Y; Okamoto F; Okamoto Y; Kato A; Hoshi S; Nagafuji M; Miyazono Y; Oshika T
Graefes Arch Clin Exp Ophthalmol; 2021 Sep; 259(9):2849-2855. PubMed ID: 33744981
[TBL] [Abstract][Full Text] [Related]
12. Refractive Error in Patients with Retinopathy of Prematurity after Laser Photocoagulation or Bevacizumab Monotherapy.
Kuo HK; Sun IT; Chung MY; Chen YH
Ophthalmologica; 2015; 234(4):211-7. PubMed ID: 26393895
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Intravitreal Bevacizumab, Intravitreal Ranibizumab and Laser Photocoagulation for Treatment of Type 1 Retinopathy of Prematurity in Turkish Preterm Children.
Kabataş EU; Kurtul BE; Altıaylık Özer P; Kabataş N
Curr Eye Res; 2017 Jul; 42(7):1054-1058. PubMed ID: 28128986
[TBL] [Abstract][Full Text] [Related]
14. Relationship between refractive outcomes and quantitative retinal vascularization and severity of plus disease in eyes treated with intravitreal bevacizumab.
Bayramoglu SE; Sayin N
Indian J Ophthalmol; 2022 Oct; 70(10):3584-3590. PubMed ID: 36190051
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal Development of Refractive Error in Children Treated With Intravitreal Bevacizumab or Laser for Retinopathy of Prematurity.
Simmons M; Wang J; Leffler JN; Li S; Morale SE; de la Cruz A; Birch EE
Transl Vis Sci Technol; 2021 Apr; 10(4):14. PubMed ID: 34003992
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Refractive Errors and Ocular Biometric Outcomes after Intravitreal Bevacizumab for Retinopathy of Prematurity.
Gunay M; Sekeroglu MA; Bardak H; Celik G; Esenulku CM; Hekimoglu E; Bardak Y
Strabismus; 2016 Jun; 24(2):84-8. PubMed ID: 27120579
[TBL] [Abstract][Full Text] [Related]
17. Refractive outcome of intravitreal bevacizumab injection in comparison to spontaneous regression of retinopathy of prematurity (ROP).
Etezad Razavi M; Shoeibi N; Hassanzadeh S; Kianmehr S; Bakhtiari E
Strabismus; 2020 Mar; 28(1):49-54. PubMed ID: 31790628
[No Abstract] [Full Text] [Related]
18. Intravitreal injection of bevacizumab for retinopathy of prematurity.
Kuniyoshi K; Sugioka K; Sakuramoto H; Kusaka S; Wada N; Shimomura Y
Jpn J Ophthalmol; 2014 May; 58(3):237-43. PubMed ID: 24566819
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of intravitreal bevacizumab for the treatment of retinopathy of prematurity: a single-center retrospective review.
Frosini S; Franco F; Vicini G; Nicolosi C; Varriale G; Dani C; Virgili G; Giansanti F
J Matern Fetal Neonatal Med; 2022 Sep; 35(17):3337-3342. PubMed ID: 32933350
[TBL] [Abstract][Full Text] [Related]
20. Low dose versus conventional dose of intravitreal bevacizumab injection for retinopathy of prematurity: a case series with paired-eye comparison.
Han J; Kim SE; Lee SC; Lee CS
Acta Ophthalmol; 2018 Jun; 96(4):e475-e478. PubMed ID: 27011262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
